[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580554":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":40,"collaborators":42,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":7,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","blood draw","Plasma samples will be collected in NTU Hospital or NTUCC. ChLIA kits and all other reagents will be provided by Volition. ChLIA analysis of samples will be performed by a Volition designated laboratory in Taiwan( NTU Centres of Genomic and Precision Medicine).",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Pei-Hsing Chen, MD","CONTACT","886-2-2312-3456 Ext. 53422","chenph@ntu.edu.tw",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Jin-Shing Chen, M.D., Ph.D.","86-2-2322-0322","chenjs@ntu.edu.tw",[24],{"facility":25,"status":26,"city":27,"state":7,"zip":7,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"National Taiwan University","RECRUITING","Taipei","Taiwan","TW",{"type":31,"coordinates":32},"Point",[33,34],121.52639,25.05306,{"lat":34,"lon":33},[37],{"name":38,"role":16,"phone":39,"phoneExt":7,"email":18},"Dobbie Pei-Hsing Chen, MD","886-2-23123456",{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[43],{"name":44,"class":45},"Volition Diagnostics UK Ltd","UNKNOWN","100580554",false,"NCT06838806","Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Differentiation","Differentiating Benign and Malignant Pulmonary Nodules Using Epigenetically Modified Nucleosomes in Plasma","Inclusion Criteria:\n\n* Aged 20 or older\n* Underwent a low-dose chest CT scan or a standard chest CT scan, showing lung nodules ≥ 6mm\n* Individuals understand the content of the consent form and are willing to participate in this study.\n* The lung nodule is assessed by a physician as high-risk, requiring thoracic surgery or biopsy for diagnosis\n\nExclusion Criteria:\n\n* Pregnant women\n* Individuals without capacity for consent, unable to understand the content of the consent form, or unwilling to participate in this study\n* Assessed by a physician as unsuitable for thoracic surgery or biopsy for diagnosis","ALL","20 Years",{"count":55,"type":56},500,"ESTIMATED","6 Months","OBSERVATIONAL","Investigators aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, investigators will investigate the potential role of Nu.Q in lung cancer prevention and its impact on survival outcomes.\n\nStudy Method:\n\nInvestigators plan to collect 20 mL of blood samples from individuals undergoing chest LDCT\u002FCT, isolate plasma for Nu.Q™ analysis, and compare the results with corresponding lung cancer pathology findings. The estimated sample size is 500 participants.",[61],"Lung Nodule",[63,64],"liquid biopsy","epigenetic","2025-11-16",{"date":67,"type":68},"2025-11-19","ACTUAL",{"date":70,"type":68},"2025-03-11",{"date":72,"type":56},"2026-03-31",{"name":5,"class":6},1]